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SP-0001   
Imaging in prostate cancer: State of art 
M. van Vulpen1 
1van Vulpen, Radiotherapy, Utrecht, The Netherlands  
 
Image Guided RadioTherapy (IGRT) is currently considered the golden 
standard in radiotherapy. Especially IGRT is required for prostate 
cancer, as the prostate is a small organ, which can show large move-
ments and where the actual tumor inside the prostate is difficult to 
detect. Imaging in prostate cancer IGRT can be divided into (1) imag-
ing before treatment for patient selection and treatment planning, (2) 
imaging during treatment to compensate for movement and (3) imag-
ing after treatment to evaluate treatment success or to detect a local 
recurrence. 
1. Imaging before treatment consists of a CT-scan and an MRI scan for 
delineation and planning purposes. MRI has optimal soft-tissue con-
trast and adds to the CT delineation, especially as it is able to show 
the location of the tumor inside the prostate. MRI usually consists of 
both anatomical sequences (T1-, T2-weighted) and functional imaging, 
like perfusion (DCE-MRI), water diffusion (DWI), metabolites (MRS), 
and several other possibilities (Figure 1). As the information on the 
location of the tumor in most sequences does not overlap, decisions 
are required to delineate the tumor. Predictive models are currently 
developed to help this decision. For detection and possible treatment 
of regional metastases and / or bone metastases MRI and Choline-PET 
are currently investigated.  
2. Imaging during treatment is meant to compensate for movement. 
Visualization of gold fiducial markers can be used for this purpose, but 
also Cone-beam CT is commonly used. An MRI-linac is under develop-
ment. In brachytherapy, ultrasound is generally used for intra-fraction 
decisions. Currently, brachytherapy (HDR and LDR applications) is 
being developed in the MRI. 
3. Post-radiotherapy a Choline PET is used to detect local recurrences 
after pervious radiotherapy (brachytherapy or external beam). It has 
high sensitivity and specificity for this purpose. For re-treatment 
(salvage) purposes MRI, including DCE and DWI, seems required to 
determine the exact location. A possible salvage treatment will start 
the IGRT loop again with the first (1) imaging part: imaging before 
treatment for patient selection and planning. 
In IGRT for prostate cancer two issues are currently explored: focal 
therapy and extreme hypofractionation. These two issues have very 
high demands with regard to imaging, like spacial accuracy, detection 
accuracy, movements, deformation, a.o. 
 
 
  
 
 
 
SP-0002   
The physics of ablative alternatives to (SB)RT 
C. Moonen1 
1University Medical Center Utrecht, Image Sciences, Utrecht, The 
Netherlands  
 
Several alternative ablative technologies, based on local temperature 
elevation, are used in medicine. They can be based on electromagnet-
ic waves in the microwave, optical, radio-frequency spectrum, or 
mechanical waves. If high spatial precision is required, High Intensity 
Focused Ultrasound (HIFU) is the only technology capable of achieving 
a local temperature increase deep inside the human body in a non-
invasive way. This presentation will deal mostly with HIFU technology. 
MRI guidance of the procedure allows in situ target definition and 
identification of nearby healthy tissue to be spared. In addition, MRI 
can be used to provide continuous temperature mapping during HIFU 
for spatial and temporal control of the heating procedure and predic-
tion of the final lesion based on the received thermal dose. The 
primary purpose of the development of MR guided HIFU was to 
achieve safe non-invasive tissue ablation.The technique has been 
tested extensively in preclinical studies, and is now accepted in the 
clinic for ablation of uterine fibroids, and for palliative treatment of 
painful bone metastases. MR guided HIFU for ablation shows concep-
tual similarities with radiation therapy. However, thermal damage 
generally shows threshold like behavior with necrosis above the 
critical thermal dose, and full recovery below. MR guided HIFU is 
being clinically evaluated in the cancer field for prostate, breast, 
liver, kidney and brain.The technology also shows great promise for a 
variety of advanced therapeutic methods such as gene and/or drug 
delivery.  
MR guided HIFU of mobile organs as kidney and liver is particularly 
challenging. Three central issues are addressed here together with 
preclinical validation: 
1) Rapid temperature mapping. Ideally, MR-Thermometry should 
achieve a sub-second temporal resolution, with minimal processing 
latencies. MR-Thermometry method was evaluated for liver and 
kidney of volunteers, and showed a precision of <2 °C in70 % of the 
pixels while delivering temperature and thermal dose maps on the fly.  
2) Intercostal HIFU firing to avoid excessive heating around the ribs. 
The ribs can be visualized on anatomical images acquired prior to 
heating and manually segmented. The resulting regions of interest are 
then projected on the transducer surface by ray tracing from the focal 
point. The transducer elements in the rib “shadow” are then deacti-
vated.  
3) Real Time MRI tracking of mobile targets for guidance of HIFU with 
sub-second 3D HIFU beam steering. The target position can be visua-
lized in 3D space by coupling rapid 2D MR imaging with prospective 
slice tracking based on pencil beam navigators 
In summary, MR guided HIFU is a promising alternative or complemen-
tary technology for ablation of tumors in many organs. It appears also 
feasible in liver and kidney but requires integration of technologically 
advanced methods.  
 
SP-0003   
Techniques and pitfalls in image registration for radiotherapy 
W. Birkfellner1 
1Medizinische Universität Wien, Center for Medical Physics and Bio-
medical Engineering, Vienna, Austria  
 
Image registration - the fusion of volume image data sets acquired 
with different modalities or at different points in time - has become a 
vital tool for radiotherapy planning in cases where hybrid imaging 
techniques are not available or not feasible. Applications range from 
comparison of target volumes over time to multimodal image fusion, 
compensation of inter- and intrafractional target volume motion, 
adaptation of dose plans and precise patient setup in image-guided 
radiotherapy. The topic of this lecture is to introduce the basic me-
thods of image registration and to highlight the possibilities and 
limitations with a special view on the requirements of radiotherapy. 
An overview of clinical applications and research perspectives will be 
given.  
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SP-0004   
Tissue characterisation for radiotherapy 
B. McClean1 
1St Luke's Hospital, Medical Physics, Dublin, Ireland Republic of  
  
The purpose of this teaching lecture is to examine typical approaches 
for representation of patient anatomical data in treatment planning 
systems and the impact of that representation on the accuracy of dose 
calculation. 
Dose calculation in modern treatment planning systems, which can 
often report dose to water or dose to medium, require mass density 
and tissue composition information for accurate kernel scaling and 
radiation transport. The planning systems use patient specific anatom-
ic information in the form of high-resolution CT images for volume 
definition and dose calculation.  CT information is obtained at kV 
energies so in order to obtain the relevant properties required for use 
in high energy photon or proton beams, the CT numbers are converted 
to electron density or proton stopping powers using calibration curves 
obtained using phantoms with known properties.  Following this, the 
patient data is resampled into a more coarse matrix and then seg-
mented into a limited number of tissue types based on, for example, 
data from ICRU44 or ICRP23, which are themselves obtained from 
population based data sets. Dose calculations are performed on these 
converted, re-sampled data sets and output as distributions on the 
original high resolution CT image set. Errors at the conversion stage 
can propagate through to dose calculation and the number of tissue 
sets used in the conversion process has been shown to have an effect 
on the dose calculation. In particular, for low energy ranges including 
brachytherapy energies, it has been shown the assignment of tissue 
properties can significantly affect dose calculation accuracy. Typical 
processes, including stoichiometric approaches, for converting CT 
data to tissue types will be described and recent data from a number 
of researchers showing the influence of the choice of conversion on 
dose calculation accuracy will be presented.   
 
SP-0005   
Improving treatment accuracy: new challenges in positioning, 
immobilisation and verification 
M. Kamphuis1, N. Wieringen van1 
1Academic Medical Center, Radiotherapy, Amsterdam, The 
Netherlands  
 
In-room patient imaging started in the 1950s. Different initiatives 
were taken to monitor and improve patient’s treatment positioning. 
Not earlier then the 1990s Electronic Portal Imaging (EPI) was devel-
oped and became commercially available. The development of EPI 
much improved both the process and the quality of the verification of 
the treatment position. The role of EPI grew and became an important 
part in the quality assurance (QA) chain of radiotherapy.  
In the last decade, 3D volumetric imaging was introduced. Nowadays 
most vendors have some kind of 3D imaging device commercially 
available. One advantage of 3D imaging is the improved quality of 
patient registration. Different studies showed improved registration 
accuracy as compared to 2D EPI. Another advantage is the ability to 
register patients directly to the tumour, e.g. in case oflung cancer. 
This not only contributed to the widespread application of Stereotac-
tic Body RadioTherapy (SBRT), but it also resulted in more insight in 
fundamental processes like the baseline shift of lung tumours. Know-
ledge about these processes further underlined the importance of 3D 
image guidance. 
More recent, the application of Adaptive Radiotherapy (ART) has 
increased and in-room volumetric imaging is a basic requirement for 
many types of the sophisticated treatment. For instance, in the Plan-
of-the-day concept a treatment plan is selected daily from a library of 
plans based on the actual size/shape of the tumour as visualised with 
Conebeam-CT (CBCT) images. This type of treatment has been intro-
duced for treatment sites like cervix and bladder cancer. Develop-
ments like ART force us to look at the changing physiology and pathol-
ogy of patients. There is a growing evidence, however, for monitoring 
anatomical changes over the course of radiotherapy in general. 
Changes in body contour for instance can be assessed easily with 3D 
imaging. A retrospective analysis of Conebeam-CT (CBCT) images from 
the NKI showed the need of replanning at some point in the treatment 
course in 15% patients treated for lung cancer. 
Besides monitoring patient position and anatomical changes, 3D 
imaging can also be used for QA goals. Questions regarding the posi-
tion of the patient relative to their immobilisation devices can be 
investigated using 3D images: e.g. is the right knee-support used, or is 
the patient well positioned on the used belly board device? In some 
cases this might give us an explanation for unstable or incorrect 
patient positioning. Also, the quality of (individual) built-up materials 
and their application can be monitored. 
With all these new possibilities the need for a systematic analysis of 
3D images is born. We no longer can perform image registration in 
terms of translation and rotations only. Ideally, the acquired images 
should be analysed on chancing anatomy and immobilization quality 
systematically, or at least at different moments during the treatment 
of the patient. Furthermore, we need to have a strategy on how to 
act when the anatomy no longer resembles the situation on the inia-
tial reference CT-scan. A protocolised method for evaluating the 
effects of anatomical changes, e.g. by recalculating the actually given 
dose using the CBCT image, would be a necessity. But maybe the most 
challenging part is finding the time and resources to be able to truly 
utilize all benefits that volumetric imaging is offering us. 
 
SP-0006   
Patient reported outcomes versus clinical assessment of radiothe-
rapy adverse effects  
J. Yarnold1 
1The Royal Marsden NHS Foundation Trust, Radiotherapy, Sutton, 
United Kingdom  
  
Patient reported outcomes (PRO) are of increasing interest as meas-
ures of disease- and treatment-related outcomes after radiotherapy. 
They have long been accepted in the palliative setting, but it is only 
recently that a primary role in the curative setting has been investi-
gated. This interest is stimulated, not only by the validity and reliabil-
ity of PRO, but also by their relative ease of administration and 
collection.  
PRO can be restricted to recording specific disease- and treatment-
related symptoms or extended to include broader qualities such as 
emotional well-being, social and sexual functioning and overall satis-
faction with life. Fully-validated multi-item questionnaires are availa-
ble, including some that are not cancer specific (MOS SF36, EQ5D) and 
others that are cancer non-site specific (EORTC QLQ-C30), cancer site 
specific (EORTC QLQ-BR23) and treatment specific (FACT N, for 
neutropenic sepsis). The identification of questionnaire(s) appropriate 
for a specific clinical context is extremely important, and requires 
expert guidance. Assuming research questions are precisely defined 
and the appropriate PRO measures are fully incorporated in the 
analysis plan, questionnaires need to be administered to patients by 
trained staff with the time to explain how to respond to the ques-
tions. As with clinician assessments, >10% missing data present serious 
problems to analysis and interpretation, since reasons for missing data 
may be linked to the outcomes under study. 
UK breast hypofractionated radiotherapy trials are among several 
studies that illustrate the potential power of PRO in research. PRO of 
breast shrinkage and hardness perform as well as change in photo-
graphic breast appearance scored by independent observers in discri-
minating small differences in randomised dose, and generate compa-
rable estimates of α/β for endpoints such as change in breast size and 
hardness. This is despite limited concordance between clinician and 
self-assessments at the level of individual patients. Although no trial 
testing curative radiotherapy has yet abandoned clinical assessments 
of treatment outcome, this may be only a matter of time. Finally, 
although PRO and standard external assessments can function well as 
therapeutic endpoints, they do not necessarily distinguish between 
the relevant pathological processes (atrophy, fibrosis, telangiectasia 
etc), a requirement that may prove essential in correlative research 
into genetic susceptibilities. 
 
SP-0007   
Consensus on brachytherapy dose - volume parameters in 2013 
T.P. Hellebust1 
1DNR - Norwegian Radium Hospital, Department of Medical Physics, 
Oslo, Norway  
  
Traditionally, treatment planning in brachytherapy has been based 
upon 2D imaging and specific points have been used for prescription 
and reporting. With the introduction of image guided brachytherapy 
(IGBT) it has been possible to move from point prescription to pre-
scription of dose to 3D target volume in terms of dose volume histo-
gram parameters.  
In radiotherapy in general, it is essential to use a common language in 
order to compare clinical results from different centres worldwide. 
Applying IGBT it is important to use a terminology adjusted to the 
complex nature of such treatment technique. Preferably the same 
terminology should be used for different brachytherapy sites. It should 
also be harmonized, as far aspossible, to the terminology used in 
external beam radiotherapy (EBRT), e.g. ICRU83. 
Several recommendations on 3D image based treatment planning have 
been published for various brachytherapy sites the last ten years. In 
an upcoming ICRU/GEC ESTRO recommendation for cervical cancer 
brachytherapy, concepts and terms for target and OAR definitions, 
biological dose modelling and DVH parameters are described for IGBT. 
